Laboratory Testing to Confirm Menopause

Age-Based Diagnostic Approach

• For women under 60, measuring both FSH and estradiol levels after 12 months of amenorrhea confirms postmenopausal status, with FSH in the postmenopausal range and low estradiol supporting the diagnosis, as recommended by the National Comprehensive Cancer Network 1
• No laboratory testing is required to diagnose menopause in women 60 years or older, as age alone is sufficient for clinical diagnosis in this population, according to the National Comprehensive Cancer Network and supported by the Journal of Clinical Oncology 1, 2
• For women under 60 with amenorrhea, the combination of elevated FSH and low estradiol provides stronger diagnostic certainty than either alone, although the exact cutoff values are not specified 1

Special Populations Requiring Testing

• For women on tamoxifen or toremifene under 60, FSH and plasma estradiol levels in postmenopausal ranges are required for diagnosis, and FSH alone is unreliable in this population, as stated by the National Comprehensive Cancer Network 1, 3
• For women with chemotherapy-induced amenorrhea, FSH is not a reliable marker of menopausal status, and serial estradiol measurements are more useful to determine return of ovarian function, according to the National Comprehensive Cancer Network and the Journal of Clinical Oncology 2, 3
• For women on GnRH agonists/antagonists, it is not possible to assign menopausal status while receiving these medications, and oophorectomy or serial hormone measurements are needed if definitive status determination is required, as recommended by the National Comprehensive Cancer Network 1

Recommended Clinical Algorithm

• For women under 60 with amenorrhea, ordering FSH and estradiol together and using local laboratory definitions of postmenopausal ranges can confirm diagnosis, as suggested by the Journal of Clinical Oncology 4
• For women on endocrine therapy or with chemotherapy history, considering serial measurements rather than single values and monitoring for clinical symptoms suggesting persistent ovarian function can be useful, according to the National Comprehensive Cancer Network and the Journal of Clinical Oncology 1, 3, 4

Diagnosing Menopause with FSH Levels

Clinical Definition of Menopause

• The National Comprehensive Cancer Network defines menopause as the permanent cessation of menses resulting from ovarian follicular depletion, with criteria including prior bilateral oophorectomy, age ≥60 years, or age <60 years and amenorrheic for ≥12 months with FSH and estradiol in the postmenopausal range 5, 6
• For women taking tamoxifen or toremifene and age <60 years, the National Comprehensive Cancer Network recommends using FSH and plasma estradiol levels in postmenopausal ranges to diagnose menopause 5, 6
• The National Comprehensive Cancer Network suggests that a menstrual history of amenorrhea for ≥12 months strongly supports a menopause diagnosis, and measuring estradiol levels concurrently with FSH can help confirm menopause, with low estradiol and high FSH supporting the diagnosis 5, 6

Hormonal Testing for Suspected Menopause

Diagnostic Approach

• The National Comprehensive Cancer Network recommends serial assessment of luteinizing hormone (LH) alongside FSH and estradiol when considering aromatase inhibitor therapy in women who become amenorrheic with chemotherapy 7
• Menopausal status cannot be determined while receiving ovarian suppression therapy, and aromatase inhibitors can stimulate ovarian function, making hormone level interpretation unreliable 7

Diagnosing Menopause Based on FSH Levels and Clinical Symptoms

Diagnostic Criteria

• For women over 45 with menopausal symptoms, FSH levels in the postmenopausal range combined with 12 months of amenorrhea and low estradiol confirm menopause, according to the National Comprehensive Cancer Network 8
• The American College of Obstetricians and Gynecologists recommends that women aged 60 years or older can be considered postmenopausal without laboratory testing, as age alone is sufficient for diagnosis 8
• For women under 60 years, both FSH and estradiol measurements are required after 12 months of amenorrhea to confirm menopause, with FSH in the postmenopausal range and low estradiol 8

Special Considerations

• The National Comprehensive Cancer Network recommends that women on tamoxifen or toremifene require both FSH and estradiol in postmenopausal ranges to confirm menopause 8
• For women on GnRH agonists/antagonists, menopausal status cannot be determined while on these medications, according to the National Comprehensive Cancer Network 8
• Women with chemotherapy-induced amenorrhea require serial estradiol measurements, as FSH is not reliable, recommends the National Comprehensive Cancer Network 8
• Premature Ovarian Insufficiency (POI) requires two elevated FSH measurements in the menopausal range, taken at least 4 weeks apart, and oligo/amenorrhea for ≥4 months, according to the American Society of Clinical Oncology 9 and the European Society of Human Reproduction and Embryology 10

Clinical Algorithm

• The American College of Obstetricians and Gynecologists recommends confirming 12 months of amenorrhea before ordering FSH and estradiol measurements in women under 60 years 8
• The National Comprehensive Cancer Network suggests measuring FSH and estradiol during the early follicular phase (days 2-5) in women with oligomenorrhea rather than amenorrhea 9
• Indeterminate results should be interpreted with caution, and serial measurements 4+ weeks apart may be necessary, recommends the American Society of Clinical Oncology 9 and the European Society of Human Reproduction and Embryology 10

NCCN Guidelines for Confirming Menopause

Special Populations Requiring Modified Hormone Testing

• Women under 60 years receiving tamoxifen or toremifene – both follicle‑stimulating hormone (FSH) and plasma estradiol must be in postmenopausal ranges to confirm menopausal status, because tamoxifen/toremifene alter hormone levels and render FSH alone unreliable. (National Comprehensive Cancer Network) 11
• Women who have completed chemotherapy – amenorrhea alone does not reliably indicate menopause, as ovarian function may persist or recover despite the absence of menses. (National Comprehensive Cancer Network) 11
• When aromatase‑inhibitor therapy is being considered after chemotherapy – confirmation of postmenopausal status requires either bilateral oophorectomy or serial measurements of both FSH and estradiol. (National Comprehensive Cancer Network) 11
• Women receiving GnRH agonists or antagonists – menopausal status cannot be assigned while these agents are active; definitive determination requires oophorectomy or serial hormone testing after discontinuation. (National Comprehensive Cancer Network) 11

Clinical Criteria That Allow a Menopause Diagnosis Without Laboratory Testing

• Prior bilateral oophorectomy is sufficient to establish menopause without any hormone measurement. (National Comprehensive Cancer Network) 11
• Age ≥ 60 years – age alone is considered adequate for a clinical menopause diagnosis. (National Comprehensive Cancer Network) 11
• Age < 60 years with ≥12 months of amenorrhea and no exposure to chemotherapy, tamoxifen, toremifene, or ovarian‑suppressing agents can be diagnosed as menopausal clinically; laboratory confirmation with FSH/estradiol adds diagnostic certainty but is not mandatory. (National Comprehensive Cancer Network) 11

Hormonal Assessment of Menopausal Status in Women < 60 Years After Hysterectomy

Diagnostic Hormone Panel

• In women younger than 60 years who have undergone hysterectomy but retain functional ovaries, clinicians should obtain a simultaneous measurement of follicle‑stimulating hormone (FSH), luteinizing hormone (LH) and serum estradiol to confirm menopausal status. 12

Interpretation of Results

• Postmenopausal status is defined by elevated FSH and LH together with low estradiol, applying the postmenopausal reference ranges used by the local laboratory. 12
• FSH alone is inadequate for classification; estradiol must be measured concurrently to verify low ovarian function. 12

Timing Relative to Therapy

• Hormone measurements must be performed before initiating any systemic therapy whose choice depends on menopausal classification, ensuring that treatment decisions are based on accurate status. 12

Hormonal Assessment for Menopausal Status in Special Populations

Women Receiving Select Breast‑Cancer Hormonal Therapies

• In patients taking tamoxifen or toremifene, menopause should be confirmed only when both follicle‑stimulating hormone (FSH) and plasma estradiol are within postmenopausal reference ranges; relying on FSH alone is unreliable because these agents alter hormone levels. (National Comprehensive Cancer Network guideline) 13

Women Treated with GnRH Agonists or Antagonists

• While on GnRH agonists or antagonists, menopausal status cannot be accurately determined; definitive classification requires either surgical oophorectomy or serial hormone testing after the medication is discontinued. (National Comprehensive Cancer Network guideline) 13

Aromatase Inhibitor (AI) Therapy

• Aromatase inhibitors may stimulate residual ovarian activity, potentially leading to a return of ovarian function. (National Comprehensive Cancer Network guideline) 13
• If a patient experiences vaginal bleeding while on an AI, immediate medical evaluation is mandated, as this may signal resumed ovarian function and necessitates reassessment of endocrine therapy. (National Comprehensive Cancer Network guideline) 13

Premature Ovarian Insufficiency (POI) Diagnosis

• For women with suspected POI (menopause before age 40), diagnosis requires two separate FSH measurements in the menopausal range taken at least four weeks apart, together with oligo‑ or amenorrhea lasting ≥4 months. (Journal of Clinical Oncology guideline) 14